Texas is paying four times more for its execution drugs from a new supplier, putting it in line with a local consumer rate but well below the cost in at least one other death penalty state. The prison agency in the nation's busiest death penalty state paid ...
Scientists are racing to begin the first human safety tests of two experimental Ebola vaccines,...
As countries try to rid themselves of toxic mercury pollution, some people are slathering and...
A Briton and an American charged with illegally trading in the personal details of Chinese nationals testified Friday that they bought such information to help companies combat fraud.
Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses.
Two American aid workers infected with Ebola are getting an experimental drug so novel it has never been tested for safety in humans and was only identified as a potential treatment earlier this year, thanks to a longstanding research program by the U.S. government and the military.
Botox and eye-drug maker Allergan is suing a Canadian drug maker and a hedge fund over their hostile takeover attempt, alleging insider trading and other fraud before their plan became public.
The Canadian company that is developing an experimental Ebola drug says its product was not given to one of two American aid workers infected with the virus.
Biologic drugmaker Amgen said Tuesday that it will lay off 12 to 15 percent of its worldwide workforce and close four sites, even as it reported stellar second-quarter results that ...
A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens.
A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.
After more than three decades of using the same three-drug combo to put hundreds of inmates to death with few problems, states have scrambled in recent years to find alternative drugs because of a shortage rooted in European opposition to capital punishment.
The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug.
The Food and Drug Administration is warning doctors not to use compounded drugs from a Texas specialty pharmacy due to risks of contamination.
A recent Health Canada inspection of the country's only flu vaccine production plant identified 10 issues that need to be addressed, a report from the regulatory agency reveals.
Botox-maker Allergan says it is cutting about 13 percent of its workforce, or roughly 1,500 employees, as part of a push to become more efficient and productive.
AbbVie has reached a roughly $55 billion deal to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from corporate income tax rates back home.
Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.
Humphrey and Yu are part of an industry of investigators who help corporate clients screen potential partners and employees or watch for embezzlement and other employee misconduct.
The generic drug maker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion.
The measure had been in the works for nearly two years, since a nationwide meningitis outbreak linked to the now-closed New England Compounding Center in Framingham. A tainted steroid produced by the company was blamed for 64 deaths and hundreds of illnesses.
Shares of Anacor Pharmaceuticals Inc. climbed after federal regulators approved its first drug, the toenail fungus treatment Kerydin, a few weeks ahead of schedule.
The European Union's antitrust body is imposing a fine of $580 million on France's pharmaceutical company Servier and five producers of generic medicines for distorting competition.
U.S. drugmaker AbbVie is boosting its offer for Shire by 11 percent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart.
Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
The bill stemmed from a nationwide meningitis outbreak that authorities blamed on a tainted steroid produced by the now-closed New England Compounding Center in Framingham. The outbreak resulted in 64 deaths and hundreds of illnesses.
- Page 1